NASDAQ · BMRN
BioMarin Pharmaceutical Inc.
$57.49+$1.49 (+2.66%)
BioMarin Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.01% below the high.
Loading market information…
NASDAQ · PHAR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pharming Group N.V.’s quoted price sits in the lower half of its reported 52-week range, 43.16% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Pharming Group N.V.’s next earnings report is currently expected on Mar 11, 2027, with estimated earnings per share of $0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pharming Group N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 31, 2025 | $0.06+160.0% vs estimate | $93.20M+12.79% vs estimate |
|---|
| Q1 2025 | May 8, 2025 | -$0.22-780.0% vs estimate | $79.09M+16.77% vs estimate |
|---|
| Q4 2024 | Mar 13, 2025 | $0.05+163.16% vs estimate | $92.70M+14.09% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $39.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$57.49+$1.49 (+2.66%)
BioMarin Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.01% below the high.
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$33.58+$0.76 (+2.32%)
Pharvaris N.V.’s quoted price sits in the upper half of its reported 52-week range, 22.36% below the high.
$8.52+$0.15 (+1.79%)
BioCryst Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.06% below the high.
$13.23-$0.09 (-0.68%)
Intellia Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.41% below the high.
$26.35-$0.06 (-0.23%)
Stoke Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.49% below the high.
$19.80+$0.09 (+0.46%)
Silence Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.33% below the high.
$2.54-$0.04 (-1.55%)
Rocket Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.39% below the high.
